CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
about
Targeted therapies and immunotherapy in non-small-cell lung cancerTackling ALK in non-small cell lung cancer: the role of novel inhibitorsNew targeted treatments for non-small-cell lung cancer - role of nivolumabTyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsCrizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancerThe distinctive nature of adenocarcinoma of the lungThe Evolution of Therapies in Non-Small Cell Lung CancerTreating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyTargeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsCombating acquired resistance to tyrosine kinase inhibitors in lung cancerCIViC databaseTwo novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibAlectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLCPersonalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practiceSecond- and third-generation ALK inhibitors for non-small cell lung cancerAlectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistanceALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome itUnderstanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule InhibitorsCrizotinib-Induced Abnormal Signal Processing in the RetinaEffect of renal function on pemetrexed-induced haematotoxicityBeyond histology: translating tumor genotypes into clinically effective targeted therapies.Molecular pathways and therapeutic targets in lung cancerNasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance statusALK-rearrangements and testing methods in non-small cell lung cancer: a reviewPooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLCThe treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approachAdverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunctionALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.Novel agents in development for advanced non-small cell lung cancer.ALK-driven tumors and targeted therapy: focus on crizotinibALK inhibitors in non-small cell lung cancer: crizotinib and beyond.Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
P2860
Q26738986-3A50D358-8A82-49B4-A794-4902B54ECDC5Q26740329-61156252-EC36-4F62-AC48-A441173A7825Q26740988-CFC503DD-0489-4F81-9A93-AF598AC580E0Q26741318-D629BE6B-3E6A-4A72-BB5A-8822E264B2CDQ26745427-BC33D392-5FA9-4854-9D1B-F818C2058F9AQ26747276-884A7FB0-90F3-4BD4-A83C-8B6D041997ACQ26769879-069BCB79-370D-4E06-AEA4-3FA2C80A5381Q26778500-3DEFD8F1-1730-426B-A548-68DEA7DC9398Q26781159-C09782E9-394D-4EA5-BB94-25A70B1C087FQ26786932-083580BF-745F-40A0-A3F0-42EE04B2A910Q26795555-77ED7076-BF22-4FF0-8453-19D60C70235FQ26799467-996B7B27-0ECE-4DEF-B6E3-38D8C2427B51Q26820845-64622A7D-93D4-46BC-8BB6-EA52820DC708Q26824877-522E8134-3CE0-4C5E-B89D-35A7C22E9150Q27612411-540EFF1F-EEF0-4B65-8A21-4747E9B01FA8Q27853072-6CC24C5F-40F4-457F-836F-32584F38A321Q27853299-00DAE324-1D42-4E02-B0FE-5C7E79906DC9Q28068643-DC043D40-5CC3-4C02-BF7B-161D5DC02E26Q28071903-0237F18E-4485-470F-96FE-005E7F937983Q28072496-A513F509-F6BC-42D3-9F7E-714F218B276DQ28081606-E96EAD59-E6F4-4535-966A-9E3123884A8BQ28083386-96FB9CD6-032D-43A6-9A0A-A65183CE0DDEQ28546245-4A55CB13-7599-46D0-BF54-B8A8521289D2Q28547218-221AF2BB-C0A9-4635-B2F5-493784DF91D9Q33432955-94BD5137-E6B3-4E8C-AD45-11B2A932FEF2Q33560928-5E3A3643-D8FA-4124-8C48-570ADB98FC8AQ33688872-1DA19BE7-0BEF-408A-B0FB-002AE6B72118Q33760992-12D5F42E-3B78-4111-ACF1-20230DB28E8FQ33776835-9BC82917-5487-4512-950B-3D10D3605007Q33791836-261C4E2D-D8F7-4F41-BCCF-10AC4C8FA2DAQ33878770-95F1D16D-A0B0-478C-B4C1-417C749E87BBQ33879009-08C21F7E-7B7A-4AEB-939C-EEE55287454FQ33882900-43111B84-A887-4170-8DF0-26795B6FAC99Q33945982-0E207D31-014D-442F-8A93-BC3F6AC41D89Q34158153-6731298C-FF32-4684-BEB4-3F41D6CD35A7Q34388696-0B55B03D-D720-42AF-A01B-3CA1AD4D8A2EQ34389263-59B01F5E-376F-4EC4-8B60-6ABA8AEFE383Q34414378-114BBDA6-9FA4-46C1-B9C5-606B794B0DCFQ34431889-05A6DDA1-3A04-4D78-8E39-605A9EDB3911Q34449807-D651957D-7684-44E9-BDB2-6338A942E9F5
P2860
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
CH5424802 (RO5424802) for pati ...... , open-label, phase 1-2 study.
@ast
CH5424802 (RO5424802) for pati ...... , open-label, phase 1-2 study.
@en
CH5424802 (RO5424802) for pati ...... , open-label, phase 1-2 study.
@nl
type
label
CH5424802 (RO5424802) for pati ...... , open-label, phase 1-2 study.
@ast
CH5424802 (RO5424802) for pati ...... , open-label, phase 1-2 study.
@en
CH5424802 (RO5424802) for pati ...... , open-label, phase 1-2 study.
@nl
prefLabel
CH5424802 (RO5424802) for pati ...... , open-label, phase 1-2 study.
@ast
CH5424802 (RO5424802) for pati ...... , open-label, phase 1-2 study.
@en
CH5424802 (RO5424802) for pati ...... , open-label, phase 1-2 study.
@nl
P2093
P3181
P1433
P1476
CH5424802 (RO5424802) for pati ...... , open-label, phase 1-2 study.
@en
P2093
Akira Inoue
Hiroshige Yoshioka
Kazuhiko Nakagawa
Kengo Takeuchi
Makoto Maemondo
Makoto Nishio
Masao Harada
Naoyuki Nogami
Nobuyuki Yamamoto
Tadashi Shimada
P3181
P356
10.1016/S1470-2045(13)70142-6
P577
2013-06-01T00:00:00Z